Gout Therapeutics Market Report 2026

Gout Therapeutics Market Overview

• Gout Therapeutics market size has reached to $3.22 billion in 2025 • Expected to grow to $5.6 billion in 2030 at a compound annual growth rate (CAGR) of 11.8% • Growth Driver: Growing Prevalence Of Gout Fuels Expansion In The Gout Therapeutics Market • Market Trend: Innovative Advances In Urate Transporter Inhibitors For Gout Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gout Therapeutics Market?

Gout therapeutics refers to medication that exerts therapeutic effects in treating the disease condition known as gout, or inflammatory arthritis, which causes pain and swelling in joints. Gout therapeutics treat and relieve pain, swelling, and tenderness in joints. The main types of gout therapeutics are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and diuretics. Non-steroidal anti-inflammatory drugs (NSAIDs) refer to drugs or medicines used for reducing inflammation, relieving pain, and bringing down a hot temperature. The various treatment includes xanthine oxidase inhibitor, and uricosuria medication used for various disease conditions such as acute, and chronic. These are used by various end-users such as hospitals, specialty clinics, and others.

What Is The Gout Therapeutics Market Growth Forecast?

The gout therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.6 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to aging population growth, chronic disease burden, preventive arthritis care, improved patient compliance tools, personalized treatment approaches. Major trends in the forecast period include rising prevalence of lifestyle-related arthritis, increased use of uric acid lowering therapies, expansion of chronic gout management, growing awareness of early diagnosis, improved long-term disease monitoring.

Global Gout Therapeutics Market Segmentation

1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Diuretics 2) By Treatment: Xanthine Oxidase Inhibitor, Uricosuria Medication 3) By Disease Condition: Acute, Chronic 4) By End-Users: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, Selective COX-2 Inhibitors 2) By Corticosteroid: Oral Corticosteroids, Injectable Corticosteroids 3) By Diuretics: Thiazide Diuretics, Loop Diuretics

What Is The Driver Of The Gout Therapeutics Market?

The rising occurrence of gout is expected to propel the growth of the gout therapeutics market going forward. Gout refers to an inflammatory arthritis condition that causes pain and swelling in joints. The rising occurrence of gout is primarily due to obesity and metabolic syndrome, which increase uric acid levels in the blood, leading to the formation of urate crystals in joints. Gout therapeutics help reduce the occurrence and severity of gout by lowering uric acid levels, managing inflammation, and preventing flare-ups. For instance,in June 2025, according to PubMed Central, a U.S.-based platform for biomedical and life sciences journals, a journal published that by 2050, age-standardized gout incidence and prevalence rates are projected to increase further, indicating the disease's rising burden worldwide. For instance, in June 2024 according to the The National Library of Medicine (NLM) a US-based largest biomedical library, in 2023, the prevalence of comorbid gout and chronic kidney disease (CKD) in the USA was 7.9 million, and it is projected to rise by 29% to reach 9.6 million by 2035 under the baseline scenario. Therefore, the rising incidence of gout is driving the growth of the gout therapeutics industry.

Key Players In The Global Gout Therapeutics Market

Major companies operating in the gout therapeutics market are Takeda Pharmaceutical Company Ltd, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, Teijin Pharma Ltd, Zydus Group, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Limited, Ironwood Pharmaceuticals Inc, Pharvaris NV, Selecta Biosciences Inc, Dyve Biosciences Inc, Arthrosi Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC

Global Gout Therapeutics Market Trends and Insights

Major companies operating in the gout therapeutics market are developing innovative products such as urate transporter for the reabsorption of uric acid from the urine back into the blood. Urate transporter is a protein that helps move uric acid (urate) across cell membranes in the kidneys or intestines, to regulate blood uric acid levels. For instance, in July 2025, Eisai Co. Ltd., a Japan-based pharmaceutical company, launched URECE (dotinurad), a selective urate transporter 1 (URAT1) inhibitor is being commercialized under Eisai’s global specialty care portfolio. URECE is used to treat hyperuricemia associated with gout, helping to lower serum uric acid levels by increasing its excretion via the kidneys. Additionally, it also offers a favorable safety profile with minimal off-target effects and efficacy in patients with mild-to-moderate renal impairment, making it suitable for a broad range of gout patients.

What Are Latest Mergers And Acquisitions In The Gout Therapeutics Market?

In October 2023, Amgen Inc, a US-based biotechnology company, acquired Horizon Therapeutics plc for an $27.8 billion. With this acquisition, Amgen aimed to strengthen and expand its rare-disease and inflammation drug portfolio, thereby broadening its therapeutic reach and accelerating revenue and growth potential. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company that specializes providing gout therapeutics

Regional Outlook

North America was the largest region in the gout therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gout Therapeutics Market?

The gout therapeutics market consists of the sales of allopurinol, benzbromarone, febuxostat, probenecid, and pegloticase drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gout Therapeutics Market Report 2026?

The gout therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gout therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.